Showing 2663 results
- Media Release /Im Zentrum des 13. International Biotechnology Leadership Camp steht das Potenzial neuer Technologien, die biomedizinische Forschung und die Pharmabranche grundlegend zu verändern Das interaktive…
- Media Release /La 13e édition de l'International Biotechnology Leadership Camp explore les nouvelles technologies susceptibles de révolutionner la recherche biomédicale et l'industrie pharmaceutique. Un programme…
- Media Release /Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's…
- Media Release /13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business Interactive program…
- Media Release /Collaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for…
- Media Release /Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
- Media Release /Pivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant…
- Media Release /Novartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with…
- Media Release /Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
- Media Release /Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated…